Skip to Content

Levadex Approval Status

  • FDA approved: No
  • Brand name: Levadex
  • Generic name: dihydroergotamine
  • Company: MAP Pharmaceuticals, Inc.
  • Treatment for: Migraine

Levadex (dihydroergotamine) is an investigational orally inhaled migraine therapy.

FDA Approval Status for Levadex

Apr 16, 2013Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Levadex (dihydroergotamine) New Drug Application
Oct 16, 2012MAP Pharmaceuticals Resubmits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug
Jun 25, 2012MAP Pharmaceuticals Provides Update Following Meeting with FDA for Levadex (dihydroergotamine) New Drug Application
Apr 12, 2012MAP Pharmaceuticals Provides Update on Levadex Program
Mar 26, 2012MAP Pharmaceuticals Receives Complete Response Letter from FDA for Levadex (dihydroergotamine) NDA
Aug 11, 2011MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Side Effects Based Upon Pharmacokinetic Profile
Aug  2, 2011MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex
May 27, 2011MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug
Jan 11, 2010MAP Pharmaceuticals Announces FDA Will Not Require a Second Pivotal Efficacy Study for Levadex NDA Submission

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.